News

The FlexStent Biliary Self Expanding Stent System is indicated for the palliative treatment of biliary strictures resulting from malignant neoplasms. The expansion of the FlexStent Biliary Stent size

Naprod Life Sciences and Pharmasyntez will sign a memorandum of understanding for setting up a manufacturing unit in Saint Petersburg, Russia, with technology transfer by Naprod. Apart from

The French regulatory authority (AFSSAPS) has authorized manufacturing operations including the production of biotechnology products, immunology products and extracted products from animal or human origin. The new facility

Under the agreement, PS Biomarker Services is expected to use a combination of its proprietary TMT isobaric mass tag technology, sample preparation and bioinformatics with Orbitrap Velos mass

The VALOR trial is expected to recruit 450 evaluable patients at sites in the US, Canada, Europe, Australia and New Zealand. In the VALOR trial, the patients will

Pro-Pharmaceuticals said that in previous experiments its polysaccharide compounds that target Galectin receptors have been shown to reverse the formation of fibrotic tissue in diseased rat livers. Scott

MorphoSys’s clinical pipeline now comprises nine partnered programs in Phase 1 and five in Phase 2 development as well as the company’s proprietary programs MOR103, which is in

‘081 is a single molecule functioning as both a muscarinic antagonist and a beta2 receptor agonist (MABA). ‘081 is an investigational compound within the inhaled bifunctional muscarinic antagonist-beta2

Merrion claims that its patented drug delivery technology, GIPET, is supported by a large database reflecting 10 years’ research and development by drug delivery experts and 21 clinical